From the Chief Executive
ABC Catalyst program a long way from objective science – The controversy over the recent ABC TV Catalyst program on cholesterol and statins has generated a lot of public debate, most of it about the integrity of the program as an impartial reporter of scientific information. The program has been criticised by a wide range of people including independent medical experts, the National Heart Foundation, the Australian
The program’s claim about statin overuse is not supported by scientific and medical evidence and the program was widely panned as biased, one-sided, unscientific and misleading. For a program that claims to report about evidence and debates in science, it’s a pretty searing criticism.
News and Updates
Medicines Australia’s submission to the National Commission of Audit, released today, shows that the key issue for the Pharmaceutical Benefits Scheme is ensuring it is fit for purpose for listing new medicines.
“The bottom line is that a lot of the work to make the PBS financially secure in the long term has already been done,” said Medicines Australia Chief Executive, Dr Brendan Shaw said today.
A new Galaxy poll of people taking prescription medicines released today reveals that Australians overwhelmingly support the Pharmaceutical Benefits Scheme, support R&D and are concerned about delays in accessing new medicines.
“This survey shows that the medicines industry’s concerns about protecting the PBS and ensuring new medicines are made available quickly are shared by the Australian community,” said Medicines Australia Chief Executive, Dr Brendan Shaw.
A new report released today by the Productivity Commission on ageing in Australia has missed the point about sustainability of the Pharmaceutical Benefits Scheme.
“It’s disappointing that today’s report by the Productivity Commission report shows the debate over PBS sustainability has not progressed much,” Medicines Australia Chief Executive, Dr Brendan Shaw, said today.
“Ten years ago we had the first Intergenerational Report singling out PBS cost projections as the villain without considering the benefits of new medical technologies to the community and the economy.
Medicines Australia announced that its new Chairman, Dr Martin Cross, is appointed from today.
“I’m delighted to be taking up this most important position for the medicines industry and the Australian community,” Dr Cross said.
“This is a critical time for the Australian medicines industry as it is facing huge challenges while also offering so much opportunity for the future.”